Production of Recombinant Conjugate Vaccine Candidates against Burkholderia pseudomallei

PDF

Authors
  1. Feldman, M.
  2. Quintanilla, F.G.
  3. Iwashkiw, J.
  4. Price, N.
Corporate Authors
Defence Research and Development Canada, Suffield Research Centre, Ralston AB (CAN);Alberta Univ, Edmonton ALTA (CAN)
Abstract
The purpose of this project was to develop a novel Burkholderia vaccine based on glycoconjugate technologies. The project involved two different vaccine directed approaches. The first project was the development of a protein glycoconjugate consisting of a Burkholderia OPS II glycan and a Campylobacter jejuni protein carrier AcrA. The second project involved exploring the use of outer membrane vesicles isolated from Escherichia coli which consisted of the Burkholderia OPS II glycan.
Keywords
burkholderia pseudomallei;recombinant glycoproteins;vaccine
Report Number
DRDC-RDDC-2014-C44 — Contract Report
Date of publication
01 Mar 2014
Number of Pages
20
DSTKIM No
CA040785
CANDIS No
802016
Format(s):
Electronic Document(PDF)

Permanent link

Document 1 of 1

Date modified: